Cargando…
Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)
OBJECTIVE: To investigate the association between total serum cholesterol (TSC) and cancer incidence in the Metabolic syndrome and Cancer project (Me-Can). METHODS: Me-Can consists of seven cohorts from Norway, Austria, and Sweden including 289,273 male and 288,057 female participants prospectively...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553083/ https://www.ncbi.nlm.nih.gov/pubmed/23372693 http://dx.doi.org/10.1371/journal.pone.0054242 |
_version_ | 1782256780414287872 |
---|---|
author | Strohmaier, Susanne Edlinger, Michael Manjer, Jonas Stocks, Tanja Bjørge, Tone Borena, Wegene Häggström, Christel Engeland, Anders Nagel, Gabriele Almquist, Martin Selmer, Randi Tretli, Steinar Concin, Hans Hallmans, Göran Jonsson, Håkan Stattin, Pär Ulmer, Hanno |
author_facet | Strohmaier, Susanne Edlinger, Michael Manjer, Jonas Stocks, Tanja Bjørge, Tone Borena, Wegene Häggström, Christel Engeland, Anders Nagel, Gabriele Almquist, Martin Selmer, Randi Tretli, Steinar Concin, Hans Hallmans, Göran Jonsson, Håkan Stattin, Pär Ulmer, Hanno |
author_sort | Strohmaier, Susanne |
collection | PubMed |
description | OBJECTIVE: To investigate the association between total serum cholesterol (TSC) and cancer incidence in the Metabolic syndrome and Cancer project (Me-Can). METHODS: Me-Can consists of seven cohorts from Norway, Austria, and Sweden including 289,273 male and 288,057 female participants prospectively followed up for cancer incidence (n = 38,978) with a mean follow-up of 11.7 years. Cox regression models with age as the underlying time metric were used to estimate hazard ratios (HR) and their 95% confidence intervals (CI) for quintiles of cholesterol levels and per 1 mmol/l, adjusting for age at first measurement, body mass index (BMI), and smoking status. Estimates were corrected for regression dilution bias. Furthermore, we performed lag time analyses, excluding different times of follow-up, in order to check for reverse causation. RESULTS: In men, compared with the 1st quintile, TSC concentrations in the 5th quintile were borderline significantly associated with decreasing risk of total cancer (HR = 0.94; 95%CI: 0.88, 1.00). Significant inverse associations were observed for cancers of the liver/intrahepatic bile duct (HR = 0.14; 95%CI: 0.07, 0.29), pancreas cancer (HR = 0.52, 95% CI: 0.33, 0.81), non-melanoma of skin (HR = 0.67; 95%CI: 0.46, 0.95), and cancers of the lymph−/hematopoietic tissue (HR = 0.68, 95%CI: 0.54, 0.87). In women, hazard ratios for the 5th quintile were associated with decreasing risk of total cancer (HR = 0.86, 95%CI: 0.79, 0.93) and for cancers of the gallbladder (HR = 0.23, 95%CI: 0.08, 0.62), breast (HR = 0.70, 95%CI: 0.61, 0.81), melanoma of skin (HR = 0.61, 95%CI: 0.42, 0.88), and cancers of the lymph−/hematopoietic tissue (HR = 0.61, 95%CI: 0.44, 0.83). CONCLUSION: TSC was negatively associated with risk of cancer overall in females and risk of cancer at several sites in both males and females. In lag time analyses some associations persisted, suggesting that for these cancer sites reverse causation did not apply. |
format | Online Article Text |
id | pubmed-3553083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35530832013-01-31 Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can) Strohmaier, Susanne Edlinger, Michael Manjer, Jonas Stocks, Tanja Bjørge, Tone Borena, Wegene Häggström, Christel Engeland, Anders Nagel, Gabriele Almquist, Martin Selmer, Randi Tretli, Steinar Concin, Hans Hallmans, Göran Jonsson, Håkan Stattin, Pär Ulmer, Hanno PLoS One Research Article OBJECTIVE: To investigate the association between total serum cholesterol (TSC) and cancer incidence in the Metabolic syndrome and Cancer project (Me-Can). METHODS: Me-Can consists of seven cohorts from Norway, Austria, and Sweden including 289,273 male and 288,057 female participants prospectively followed up for cancer incidence (n = 38,978) with a mean follow-up of 11.7 years. Cox regression models with age as the underlying time metric were used to estimate hazard ratios (HR) and their 95% confidence intervals (CI) for quintiles of cholesterol levels and per 1 mmol/l, adjusting for age at first measurement, body mass index (BMI), and smoking status. Estimates were corrected for regression dilution bias. Furthermore, we performed lag time analyses, excluding different times of follow-up, in order to check for reverse causation. RESULTS: In men, compared with the 1st quintile, TSC concentrations in the 5th quintile were borderline significantly associated with decreasing risk of total cancer (HR = 0.94; 95%CI: 0.88, 1.00). Significant inverse associations were observed for cancers of the liver/intrahepatic bile duct (HR = 0.14; 95%CI: 0.07, 0.29), pancreas cancer (HR = 0.52, 95% CI: 0.33, 0.81), non-melanoma of skin (HR = 0.67; 95%CI: 0.46, 0.95), and cancers of the lymph−/hematopoietic tissue (HR = 0.68, 95%CI: 0.54, 0.87). In women, hazard ratios for the 5th quintile were associated with decreasing risk of total cancer (HR = 0.86, 95%CI: 0.79, 0.93) and for cancers of the gallbladder (HR = 0.23, 95%CI: 0.08, 0.62), breast (HR = 0.70, 95%CI: 0.61, 0.81), melanoma of skin (HR = 0.61, 95%CI: 0.42, 0.88), and cancers of the lymph−/hematopoietic tissue (HR = 0.61, 95%CI: 0.44, 0.83). CONCLUSION: TSC was negatively associated with risk of cancer overall in females and risk of cancer at several sites in both males and females. In lag time analyses some associations persisted, suggesting that for these cancer sites reverse causation did not apply. Public Library of Science 2013-01-23 /pmc/articles/PMC3553083/ /pubmed/23372693 http://dx.doi.org/10.1371/journal.pone.0054242 Text en © 2013 Strohmaier et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Strohmaier, Susanne Edlinger, Michael Manjer, Jonas Stocks, Tanja Bjørge, Tone Borena, Wegene Häggström, Christel Engeland, Anders Nagel, Gabriele Almquist, Martin Selmer, Randi Tretli, Steinar Concin, Hans Hallmans, Göran Jonsson, Håkan Stattin, Pär Ulmer, Hanno Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can) |
title | Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can) |
title_full | Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can) |
title_fullStr | Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can) |
title_full_unstemmed | Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can) |
title_short | Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can) |
title_sort | total serum cholesterol and cancer incidence in the metabolic syndrome and cancer project (me-can) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553083/ https://www.ncbi.nlm.nih.gov/pubmed/23372693 http://dx.doi.org/10.1371/journal.pone.0054242 |
work_keys_str_mv | AT strohmaiersusanne totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT edlingermichael totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT manjerjonas totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT stockstanja totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT bjørgetone totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT borenawegene totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT haggstromchristel totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT engelandanders totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT nagelgabriele totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT almquistmartin totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT selmerrandi totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT tretlisteinar totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT concinhans totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT hallmansgoran totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT jonssonhakan totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT stattinpar totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan AT ulmerhanno totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan |